HALO BIOSCIENCES, INC.

Biotech · Private

4-methylumbelliferone (4-MU) formulation (H1614) — a small molecule inhibitor of hyaluronan synthesis for pulmonary hypertension due to interstitial lung disease

Grants
$3.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH)$1,957,305
Federal grantDepartment of Health and Human Services · Phase II · Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH)$1,036,071
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2311Vivace Therapeutics—$61M
2312Volta Labs, Inc.—$29M
2313FabricNano Inc.—$21M
2314HALO BIOSCIENCES, INC.——
2315Bond Biosciences, Inc.—$18M
2316Moleculin Biotech, Inc.—$6.0M
2317ProtoKinetix, Inc.—$3.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.